Evidence supporting the use of: Honokiol
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Honokiol, a bioactive compound extracted from the bark of Magnolia species, has been investigated in preclinical studies for its neuroprotective effects relevant to Parkinson’s Disease (PD). The scientific interest arises from honokiol's antioxidant, anti-inflammatory, and anti-apoptotic properties, which are mechanisms implicated in the pathophysiology of PD. Several in vitro and animal studies have shown that honokiol can reduce dopaminergic neuronal death, inhibit microglial activation, and decrease oxidative stress in models simulating PD, such as those using the neurotoxins MPTP or rotenone. For example, a 2018 study in "Frontiers in Pharmacology" demonstrated that honokiol pretreatment alleviated behavioral impairments and dopaminergic neuron loss in MPTP-induced mouse models of PD. Additionally, honokiol appears to modulate mitochondrial function and may influence pathways like Nrf2, which is involved in cellular antioxidant defense. However, the evidence supporting honokiol’s use in human PD patients is currently lacking; there are no published clinical trials evaluating its efficacy or safety in this population. The existing animal and cellular data are promising, suggesting neuroprotective potential, but translation to human therapy remains unproven. Therefore, while there is a scientific rationale based on preclinical research, the overall evidence is limited and further clinical studies are needed to determine its therapeutic value for Parkinson's Disease.

More about Honokiol
More about Parkinson's Disease

Products containing Honokiol

We currently have no products on Vitabase that contain this ingredient.